NEW YORK, October 26, 2016 /PRNewswire/ --
Stock-Callers.com is closely reviewing the most recent performances of four major players in the Drug Manufacturers space: Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). These companies belong to the Healthcare sector which was little changed from its mid-day declines on Tuesday, October 25, 2016, with the NYSE Health Care Index slipping about 0.5%, and shares of health care companies in the S&P 500 declining 0.2% as a group. Learn more about these stocks by accessing their free research reports at:
New York headquartered Pfizer Inc.'s shares rose 0.47% and finished Tuesday's trading session at $32.28. A total volume of 19.32 million shares was traded, which was above their three months average volume of 18.96 million shares. Since the start of this year, the stock has advanced 2.76%. The Company's shares are trading below their 200-day moving average by 1.43%. Moreover, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have a Relative Strength Index (RSI) of 32.20.
On October 13th, 2016, research firm Jefferies downgraded the Company's stock rating from 'Buy' to 'Hold'.
On October 21st, 2016, Astellas Pharma Inc. and Pfizer announced the U.S. Food and Drug Administration approved a supplemental New Drug Application to update the U.S. product labeling for XTANDI® (enzalutamide) capsules to include new clinical data versus bicalutamide from the TERRAIN study. The data demonstrate improvement in radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer who were treated with enzalutamide compared to patients who were treated with bicalutamide. Free research report on PFE is available at:
On Tuesday, shares in Kenilworth, New Jersey headquartered Merck & Co. Inc. recorded a trading volume of 15.12 million shares, which was above their three months average volume of 10.25 million shares. The stock ended the session 1.98% higher at $61.95. The Company's shares have gained 6.49% in the previous three months and 20.15% on an YTD basis. The stock is trading 10.39% above its 200-day moving average. Furthermore, shares of Merck, which provides health care solutions worldwide, have an RSI of 48.91.
On October 13th, 2016, research firm Bank of America/ Merrill upgraded the Company's stock rating from 'Neutral' to 'Buy'.
On October 25th, 2016, Merck reported that worldwide sales were $10.5 billion for Q3 2016, an increase of 5% compared with Q3 2015, including a 1% negative impact from foreign exchange. For Q3 2016, GAAP EPS assuming dilution were $0.78 compared to EPS of $0.64 in Q3 2015. Q3 2016 pharmaceutical sales increased 6% to $9.4 billion. The complimentary research report on MRK can be downloaded at:
Shares in Illinois-based AbbVie Inc. closed the day at $61.55, up 0.70%. The stock recorded a trading volume of 6.41 million shares, which was higher than its three months average volume of 6.16 million shares. The Company's shares have gained 7.92% on an YTD basis, and are trading 3.07% above their 200-day moving average. Additionally, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have an RSI of 45.56.
On October 18th, 2016, research firm Leerink Partners initiated a 'Market Perform' rating on the Company's stock, issuing a target price of $70 per share.
On October 19th, 2016, AbbVie in cooperation with Neurocrine Biosciences, Inc. announced detailed results from two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of Elagolix in premenopausal women who suffer from endometriosis. The data demonstrate that, compared to placebo at month three and month six, patients treated with Elagolix reported statistically significant reductions in scores for menstrual pain and non-menstrual pelvic pain associated with endometriosis as measured by the Daily Assessment of Endometriosis Pain scale. Visit us today and access our complete research report on ABBV at:
Johnson & Johnson
At the closing bell yesterday, shares in New Brunswick, New Jersey-based Johnson & Johnson ended 0.31% higher at $113.96 and with a total trading volume of 5.59 million shares. The stock has advanced 13.29% since the start of this year. The Company's shares are trading above their 200-day moving average by 1.18%. Furthermore, shares of Johnson & Johnson, which together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide, have an RSI of 34.94.
On October 19th, 2016, research firm UBS reiterated a 'Buy' rating on the Company's stock with an increase of the target price from $137 a share to $144 a share.
On October 20th, 2016, Johnson & Johnson' Board of Directors declared a cash dividend for Q4 2016 of $0.80 per share. The dividend is payable on December 6th, 2016 to shareholders of record at the close of business on November 22nd, 2016. Get free access to your research report on JNJ at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA